2019, September 19-20: Updates of the WHO Classification of Brain and Pituitary Tumors
September 19-20, 2019
16 CME / 16 SAMs
For the first time, the 2016 WHO classification of central nervous system (CNS) tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. These new updates will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors. General pathologists, in particular, must become familiar with changes in diagnostic criteria and utilize them in their practice improvement strategies. The WHO classification of pituitary adenomas was revised in 2017 and includes (1) a recommendation for the assessment of pituitary transcription factors with focus on adenohypophysial-cell lineage and (2) replacement of “atypical adenoma” with “high risk adenoma” based on tumor proliferation markers and other clinical parameters (such as invasion) to predict aggressiveness. This course will illustrate and reinforce these important updates.
- Apply the cIMPACT-NOW and 2016 updates to the WHO classification for the diagnosis of adult diffuse gliomas
- Utilize morphologic and molecular diagnostic techniques to diagnose pediatric brain tumors
- Explain the role of integrated molecular and histological criteria in the classification of other CNS tumors including dural and embryonal neoplasms
- Summarize the changes in neuroendocrine and non-neuroendocrine pituitary tumor classification
- Apply the 2017 update to the WHO classification of pituitary tumors to the diagnosis of sellar region tumors
- Arie Perry, M.D.
University of California, San Francisco
- Maria Beatriz S. Lopes, M.D., Ph.D.
University of Virginia, Charlottesville
- Fausto J. Rodriguez, M.D.
Johns Hopkins University School of Medicine
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC).
Physicians can earn a maximum of 16 SAM credit hours.
USCAP records courses at the Interactive Learning Center for future educational purposes. By registering for this course, you consent that your likeness may be used by USCAP.
For cancellations received on or before one month before the event, a $50 administrative charge will be due. After that date, cancellations will be assessed an administrative charge of 25% of the total registration fee. There will be no refunds for cancellations after one week before the event.
The Academy is not responsible for travel expenses incurred as a result of an event cancellation.